Statistics for Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Total visits
| views | |
|---|---|
| Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). | 1 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 1 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
Top country views
| views | |
|---|---|
| Ukraine | 1 |